Estimations des analystes de Wall Street pour Coherus Oncology, Inc. (CHRS): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.21 | ||
| 2026-08-05 | $-0.19 | $-0.25 | +24.0% |
| 2026-05-11 | $-0.25 | $-0.26 | +5.1% |
| 2026-03-09 | $-0.34 | $-0.36 | +4.2% |
| 2025-11-06 | $-0.33 | $-0.32 | -3.1% |
| 2025-08-07 | $-0.34 | $-0.31 | -9.7% |
| 2025-05-12 | $-0.35 | $-0.31 | -12.9% |
| 2025-03-10 | $-0.44 | $-0.10 | -340.0% |
Ratios de valorisation
| Prix / Valeur comptable | 2.98 |
| EV / EBITDA | -1.12 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $190.1M | $1.6M | $1.6M | $356.1M | $475.8M | $326.6M | $211.0M | $257.2M | $267.0M | $42.2M |
| Coût des Ventes | $254.4M | $160.5M | $3.2M | $17.1M | $37.7M | $57.6M | $70.1M | $159.0M | $117.6M | $17.7M |
| Marge Brute | -$64.3M | -$159.0M | -$1.7M | $339.0M | $438.2M | $269.0M | $141.0M | $98.3M | $149.4M | $24.4M |
| R&D | $254.4M | $162.4M | $110.2M | $94.2M | $142.8M | $363.1M | $199.4M | $109.4M | $93.3M | $105.0M |
| Frais Généraux | $51.6M | $71.3M | $94.2M | $137.0M | $139.1M | $169.7M | $198.5M | $185.6M | $150.4M | $99.0M |
| Charges Opérationnelles | $306.0M | $233.7M | $204.4M | $231.2M | $281.8M | $532.8M | $397.8M | $301.5M | $261.1M | $204.0M |
| Résultat Opérationnel | -$115.9M | -$232.1M | -$204.4M | $107.8M | $156.3M | -$263.9M | -$256.9M | -$203.2M | -$111.7M | -$179.5M |
| EBITDA | -$116.8M | -$225.3M | -$204.4M | $111.0M | $161.8M | -$260.7M | -$255.6M | -$193.9M | $60.9M | -$170.2M |
| Charges d'Intérêt | $8.0M | $9.6M | $9.7M | $17.6M | $21.2M | $23.0M | $32.5M | $40.5M | $27.2M | $9.0M |
| Résultat Avant Impôts | -$127.8M | -$238.3M | -$209.4M | $92.8M | $135.7M | -$287.1M | -$291.8M | -$238.3M | $28.5M | -$183.1M |
| Impôts | $656000 | 0 | 0 | $2.9M | $3.5M | 0 | 0 | -$380000 | 0 | 0 |
| Résultat Net | -$127.3M | -$238.2M | -$209.3M | $89.8M | $132.2M | -$287.1M | -$291.8M | -$237.9M | $28.5M | -$170.3M |
| BPA | $-3.04 | $-4.48 | $-3.22 | $1.29 | $1.85 | $-3.81 | $-3.76 | $-2.53 | $0.25 | $-1.45 |
| BPA Dilué | $-3.04 | $-4.48 | $-3.22 | $1.23 | $1.62 | $-3.81 | $-3.76 | $-2.53 | $0.25 | $-1.45 |
| Actions en Circulation (Diluées) | $41.9M | $53.1M | $65.0M | $73.2M | $83.5M | $75.4M | $77.6M | $94.2M | $114.8M | $120.4M |
Prix
| Prix | $1.22 |
| Capitalisation | $188M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: AVTX · CCCC · CDXS · IMDX · IVVD · OABI · PLX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de CHRS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions